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Abstract
Background: Parvovirus H-1 (H-1PV) infects and lyses human tumor cells including melanoma, hepatoma, gastric,
colorectal, cervix and pancreatic cancers. We assessed whether the beneficial effects of chemotherapeutic agents
or targeted agents could be combined with the oncolytic and immunostimmulatory properties of H-1PV.
Methods: Using human ex vivo models we evaluated the biological and immunological effects of H-1PV-induced
tumor cell lysis alone or in combination with chemotherapeutic or targeted agents in human melanoma cells +/-
characterized human cytotoxic T-cells (CTL) and HLA-A2-restricted dendritic cells (DC).
Results: H-1PV-infected MZ7-Mel cells showed a clear reduction in cell viability of >50%, which appeared to occur
primarily through apoptosis. This correlated with viral NS1 expression levels and was enhanced by combination
with chemotherapeutic agents or sunitinib. Tumor cell preparations were phagocytosed by DC whose maturation
was measured according to the treatment administered. Immature DC incubated with H-1PV-induced MZ7-Mel
lysates significantly increased DC maturation compared with non-infected or necrotic MZ7-Mel cells. Tumor
necrosis factor-a and interleukin-6 release was clearly increased by DC incubated with H-1PV-induced SK29-Mel
tumor cell lysates (TCL) and was also high with DC-CTL co-cultures incubated with H-1PV-induced TCL. Similarly,
DC co-cultures with TCL incubated with H-1PV combined with cytotoxic agents or sunitinib enhanced DC
maturation to a greater extent than cytotoxic agents or sunitinib alone. Again, these combinations increased pro-
inflammatory responses in DC-CTL co-cultures compared with chemotherapy or sunitinib alone.
Conclusions: In our human models, chemotherapeutic or targeted agents did not only interfere with the
pronounced immunomodulatory properties of H-1PV, but also reinforced drug-induced tumor cell killing. H-1PV
combined with cisplatin, vincristine or sunitinib induced effective immunostimulation via a pronounced DC
maturation, better cytokine release and cytotoxic T-cell activation compared with agents alone. Thus, the clinical
assessment of H-1PV oncolytic tumor therapy not only alone but also in combination strategies is warranted.
Background
The inherent host tumor immunosurveillance system
combats the formation and growth of tumors, mainly
relying on the interaction of effector immune cells with
the tumor cells [1]. Activation of tumor-specific cyto-
toxic T-lymphocytes (CTL) requires presentation of
tumor-associated antigens (TAAs) primarily by dendritic
cells (DC), in addition to the helper functions of CD4
+
cells [2]. For this reaction to proceed, immature DC
with high endocytic activity must differentiate into
mature DC with increased expression of co-stimulatory
molecules that prime and boost T-cell and B-cell func-
tions [3]. The implementation of these immune reac-
tions into anti-tumor therapy is desirable but cannot be
satisfactorily achieved in many situations through classi-
cal systemic therapy alone.
Recently, we and other groups demonstrated the
induction of increasing immune reactions using
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ex vivo and in vivo tumor xenograft models [4-6]. Parvo-
viruses or other viruses employed as therapeutic gene
vectors are used to stimulate the immune system [6-8].
However, many of these vectors are restricted by their
pathogenicity and adverse immunological side-effects
[9]. Non-pathogenic parvovirus H-1 (H-1PV), depending
on the target cells and culture conditions, induced apop-
tosis or autophagy-like cell death [8,10-12]. Besides gen-
uine oncolytic activity, Bhat et al showed that targeted
tumor cell H-1PV infection and the improved recogni-
tion as target cells by natural killer (NK) cells leads to
an amplification of NK cell-mediated immune response
[13]. Furthermore, H-1PV efficiently induced viral onco-
lysis in Burkitt’s lymphoma cells, including those resis-
tant to apoptosis induction by rituximab [14]. In
addition, H-1PV could activate human anti-tumor
immune response by adoptive transfer and an abortive
H-1PV infection of human peripheral blood mononuc-
lear cells (PBMC) [15]. Thus, H-1PV efficiently activated
the human immune system and may potentially support
classical systemic chemotherapy and/or new molecular
targeted agents in the treatment of human cancer
patients [10,16].
Parvoviruses are small nuclear DNA viruses that repli-
cate during S-phase of the cell cycle. H-1PV efficiently
infects human tumor cells, including melanoma, hepa-
toma, colon and gastric cancer cells [8,10,17]. Moreover,
parvovirus productive lytic infection resulted in reduced
incidence of spontaneous, virally, and chemically
induced tumors in animals [8,18]. In contrast to these
fast-replicating cells, human immune cells and primary
hepatocytes cannot be infected or lysed [8,10,15]. More-
over, recombinant parvoviruses that are deficient in
replication have been engineered to deliver immunosti-
mulating molecules to increase their anti-tumor proper-
ties [8,18,19]. We further reported that immunogenic
heat shock proteins are released during the process of
H-1PV-induced killing of human melanoma cells,[6,10]
and demonstrated increased phagocytosis of H-1PV-
induced tumor cell lysates (TCL) leading to increased
maturation of DC. These activated DC improved tumor
antigen presentation with stimulation of TAA-specific
CTL via cross presentation [6].
So far, the immunological effects of combining H-1PV
and conventional chemotherapeutic agents or newer tar-
geted agents are yet unknown. Thus, the aim of the cur-
rent study was to analyze the putative synergistic
biological and immunological effects of H-1PV com-
bined with cisplatin, vincristine or the multi-tyrosine
kinase (TK) inhibitor, sunitinib, in human tumor and
immune cells. We employed human melanoma models,
which allowed the study of immune responses in the
context of corresponding HLA-restricted human DC.
This human ex vivo tumor model with tumor-specific
autologous CTL clones was also used with HLA-A2-
positive and HLA-A2-negative melanoma variant cells
[6]. Since new molecular targeted therapies, including
sunitinib, erlotinib or sorafenib, are increasingly being
approved for treatment of many human cancers, due to
their combined tumor-suppressive and anti-angiogenic
effects,[20,21] their combinations with H-1PV may be
even more attractive to induce CTL. Therefore, we
aimed to develop a more effective DC-mediated immune
stimulation by combining chemotherapeutic or targeted
agents with H-1PV.
Methods
Human cancer cells and primary human immune cells
Human melanoma cell lines MZ7-Mel, SK29-Mel-1 and
SK29-Mel-1.22 were cultured as previously described
[10]. The autologous melanoma line MZ7-MEL was
established from a splenic metastasis in 1988. MZ7-
MEL expressed MAGE-A3, tyrosinase, Melan-A/MART-
1 and gp100 [22]. The SK29-Mel-1.22 cell line is a
selected HLA-A2 negative (A2
-)v a r i a n to fH L A - A 2 -
positive (A2
+) SK29-Mel-1 cells [23]. The HLA-A2-
restricted CTL line, CTL IVSB, directed against the
TAA tyrosinase peptide 369-376 [24] was derived from
an autologous mixed lymphoid tumor cell culture of the
SK29-model. These cells and the EBV-transformed B-
cell line (MZ-EBV-B) were obtained as a gift from T.
Woelfel (Mainz, Germany). CTL were maintained in
long-term culture by passaging every 4-7 days [24]. Pri-
mary human immune cells (monocytes, immature and
mature DC) were derived from buffy coats of healthy
blood donors in the Department of Transfusion Medi-
cine of Johannes Gutenberg University Mainz (Mainz,
Germany) and used as described [6,25]. For the use of
samples from healthy blood donors no ethical approval
was needed.
Virus preparation and infection of tumor cells
Wild-type H-1PV was produced in NB-324K cells and
purified on iodixanol gradients. For wild-type virues
titers are determined by plaque assays as previously
described [26] and the multiplicity of infection (MOI)
is given by the number of plaque-forming units (PFU).
To infect tumor cells with H-1PV, medium of expo-
nentially growing cell cultures were removed and then
incubated for one hour with H-1PV at a MOI of 20
PFU/cell in minimal amount of complete medium
(Minimum Essential Medium, 5% FCS, 1% glutamine,
1% penicillin/streptomycin; Life Technologies, Karls-
ruhe, Germany) and than fill up to appropriate amount
of medium according to the size of dishes, plates and
flasks. Cells were cultured for up to 10 days post infec-
tion (p.i.).
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For combined treatment, cells were firstly infected with
H-1PV in complete medium (described above) and one
hour or 24 hours after infection, chemotherapeutic
agents or sunitinib were added by adding appropriate
amount of medium and cells were incubated until analy-
sis. Cisplatin and vincristine were purchased from Gry
Pharma GmbH (Kirchzarten, Germany) and freshly dis-
solved in medium to a concentration from 0.1 μg/ml to
5 μg/ml, a concentration of 0.1 μg/ml was used for ana-
lysis. Sunitinib (sunitinib malate, SUTENT
®;P f i z e rI n c . )
was provided by Pfizer (Pfizer, NY, USA), and was dis-
solved in dimethylsulfoxide (Invitrogen, Karlsruhe, Ger-
m a n y )f r o m1 - 5μg/ml and a concentration of 5 μg/ml
was used for analysis.
Virus-driven transgene expression and protein analyses
For measurement of transient H-1PV expression, virus
particles were quantified by luciferase expression using
the NS-proficient recombinant parvovirus hH1Δ1600luc
(carries firefly luciferase gene instead of viral caspid pro-
teins) as described previously [8]. Infections were per-
formed for 1 hour at a MOI of 10-2 RU/cell. For
recombinant viruses titers are determined by infected
cell hybridization assays and are expressed as replication
units (RU) per milliliter of virus suspension. Finally,
cells were harvested on days 3 and 4 p.i. Luciferase
activities were determined with a Luminometer (Bert-
hold, bad Wildbad, Germany) and expressed as level of
induction relative to control. NS1 was analyzed by wes-
tern blotting as previously described [8,11]. Blots were
incubated with the rabbit polyclonal antibody SP8
(1:1000) directed against carboxy-terminal peptides of
NS1,[27] and processed for enhanced chemolumines-
cence detection (Amersham Pharmacia Biotech, Frei-
burg, Germany).
H-1PV-induced cytotoxicity and analysis of apoptosis
To quantify cellular cytotoxicity, cells infected with H-
1PV and/or treated with chemotherapeutic agents or
sunitinib were grown for up to 6 days and stained with
crystal violet for 1 hour. Measurements were performed
at 550 nm at day 4 and 6 p.i. The growth inhibition
(percentage of survival) was defined as percentage
reduction of photometric absorption measurements of
H-1PV-infected versus non-infected cell cultures. The
absorption was measured via an enzyme-linked immu-
nosorbant assay (ELISA) reader. The results were pre-
sented as relative to the control value (untreated cells).
Cell viability of H-1PV infection 1 or 24 hours p.i., in
addition to sunitinib treatment alone or in combination
with H-1PV, was monitored by the 2-(4,5-dimethyltria-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Bio-
mol, Hamburg, Germany) colorimetric assay. The
absorbance was measured at 570 nm. Percent viability
was defined as the relative absorbance of treated versus
untreated control cells. To quantify the percentage of
apoptotic cells in H-1PV-infected cultures (MOI = 20
PFU/cell), adherent cells were dissociated via trypsiniza-
tion and collected 3 days p.i. by centrifugation at 800 ×
g. The harvested cells were processed as described pre-
viously [11]. Levels of apoptosis were assessed by FACS-
can flow cytometry with Cell Quest software (Becton
Dickinson, Heidelberg, Germany) according to the man-
ufacturer’s instructions [8].
Immunologic analysis for DC phagocytic activity,
maturation, cross presentation and cytokine release
For phagocytic activity and maturation, DC were labeled
with PKH2 and melanoma cells with PKH26. Labeled
melanoma cells were infected with H-1PV (MOI = 20
PFU/cell). On day 10 p.i., TCL from H-1PV-infected
melanoma were incubated for 2 days with PKH2-stained
immature DC at a ratio of 1:3 in a 24-well plate. Non-
infected melanoma cells, UV-irradiated (200 J/m
2)a n d
ultrasonicated tumor cells were stained with PKH26
prior to UV-irradiation and sonication and used as con-
trols. To gate out mature DC from immune and dead
cells, cells were treated as described previously [6]. After
1 day of co-culture, PKH2-labeled DC were analyzed for
uptake of PKH26-stained melanoma TCL by FACS. DC
staining was performed with phycoerythrin-labeled anti-
bodies against human CD80, CD83 and CD86, and con-
trolled with appropriate isotype-matched antibodies as
previously described [6]. Expression levels were mea-
sured by FACScan after immature DC were incubated
with untreated melanoma cells, UV-irradiated melanoma
cells or H-1PV-infected melanoma cells 10 days p.i..
To explore the maturation status of DC incubated
with H-1PV-infected TCL combined with chemothera-
peutic agents, SK29-Mel cells were infected with H-
1PV (MOI = 20 PFU/cell). After one hour of viral
infection, either vincristine or cisplatin was added into
the medium. These 6-days differently incubated mela-
noma cells were co-cultured with immature DC for 2
days. Immature DC were marked with phycoerythrin-
labeled antibodies against human CD86 and measured
by FACScan [6].
To measure inflammatory cytokines from DC, imma-
ture DC were co-cultured with TCL from H-1PV-
infected or with non-infected cells for 1 day in 96-well
plates in a ratio of 1:3. As a control, the production of
cytokines in melanoma cells, H-1PV-infected melanoma
cells, and of immature and mature DC was measured.
Mature DC controls were obtained by adding a cytokine
cocktail as previously described [28]. Supernatants were
prepared by aspirating media from the co-culture and
by diluting 1:1 with fresh medium. Tumor necrosis
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mined by ELISA kits (BD Biosciences Pharmingen)
according to the manufacturer’s protocol.
Results
Cytotoxicity of H-1PV-infected MZ7-Mel cells, expression
of H-1PV proteins and virus-driven transgenes
The cytotoxic effect of H-1PV in MZ7-Mel cells was
determined by time-dependent measurement of cell
growth (Figure 1A). H-1PV infection of MZ7-Mel cells
with an MOI of 20 resulted in an approximately 50%
reduction of cell growth at day 4 and 6 p.i.. Six days p.i,
cells continued to grow, but with a significantly reduced
growth rate compared to controls. This may be due to
the fact that a threshold of NS1 has to be present to
induce cell cycle arrest. Until critical NS1 levels occur,
cells can proliferate [29]. Time-dependent expression of
the viral non-structure protein NS1 was documented in
MZ7-Mel cells by western blotting at 1 day p.i. with the
highest expression levels found 2 days p.i. (Figure 1B).
On day 6 p.i., NS1 expression decreased, most likely due
to H-1-mediated induction of apoptosis. Further results
o ft h el u c i f e r a s ea s s a yu s i n gp a r v o v i r u sh H 1 Δ1600luc
[11] indicated a more than 200-fold induction of lucifer-
ase activity 3 days p.i. compared with non-infected cells
(Figure 1C). Luciferase activity was further enhanced 4
days p.i. Thus data suggest that H-1PV-induced cell kill-
ing was correlated with NS1 [8,30].
Analysis of DC activity: phagocytosis and maturation
The immunogenicity of tumor cells was determined by
phagocytosis and the presentation of tumor antigens by
DC [31]. We therefore investigated the activation of DC
following co-culture with H-1PV-induced MZ7-Mel
lysates compared with a panel of control MZ7-Mel cell
preparations. Phagocytosis of MZ7-Mel preparations by
immature DC was quantified by flow cytometry (Figure
1D). The highest proportion of phagocytosing DC
(PKH2 and PKH26 double-staining) was 38%, detected
after co-incubation with TCLs from H-1PV-infected
MZ7 Mel 10 days p.i., compared with ~29% DC coincu-
bated with UV-irradiated and ultrasonic-treated tumor
cells respectively, and 16% from untreated melanoma
cells. Thus, phagocytosis in immature DC was most
effectively stimulated by H-1PV-induced melanoma cell
lysates.
As previously been shown [25], treatment of immature
DC with a cocktail of pro-inflammatory cytokines led to
DC maturation characterized by a major increase in
CD80, CD83 and CD86 expression (data not shown). In
order to investigate whether H-1PV-induced melanoma
cell lysates modulate DC maturation, the expression of
these surface markers was analyzed following incubation
with H-1PV-induced melanoma cell lysates taken 10
days p.i. compared with incubation with control MZ7-
Mel cell preparations (Figure 1E). DC co-cultured with
melanoma cells alone did not present significant pheno-
typic characteristics of DC maturation (CD80: ~5%,
CD83: ~6%, CD86: ~10%), and co-culture with UV-irra-
diated apoptotic cells led to a non-significant increase of
CD83 markers only (~11%). However, DC incubated
with H-1PV-induced MZ7-Mel lysates resulted in a dra-
matic increase of all DC maturation markers, clearly
indicating DC maturation (CD80: ~45%, CD83: ~52%,
CD86: ~37%) (Figure 1E).
Cell viability after treatment with H-1PV,
chemotherapeutic or targeted agents
The viability of melanoma cells was assessed after expo-
sure with cisplatin, vincristine alone, or together with
H-1PV infection 24 hours p.i. using MTT assays. Cispla-
tin alone reduced SK29-Mel viability (Figure 2A). The
reduction of cell viability was additionally enhanced
when cisplatin was combined with H-1PV. Enhancement
of cisplatin-mediated apoptosis was observed in the pre-
sence of H-1PV, suggesting apoptosis may contribute to
the reduced viability observed with the combination
(Figure 2B). Similar effects were demonstrated with vin-
cristine (data not shown).
We next quantified the effect of H-1PV infection in
combination with sunitinib on cell viability of SK29-Mel
cells. Sunitinib alone led to a decrease in SK29-Mel via-
bility after 24 hours of treatment with the optimal con-
centration of 5 μg/ml. The combination of sunitinib
with H-1PV led to a further reduction of SK29-Mel cell
viability (Figure 3A) and was dependent on the time-
point of exposure. Application 1 hour p.i. led to
decreased cell viability of ~50% compared with H-1PV
treatment alone (Figure 3B). In contrast, treatment 24
hours p.i. led to a 24% decrease in cell viability (data
not shown). The combination of cisplatin with H-1PV
also led to a reduction of cell viability, by 20% when
administered at 1 hour p.i (Figure 3B) and by 23% admi-
nistered 24 hour p.i. (data not shown), indicating no sig-
nificant differences between administration of
chemotherapeutic agents at 1 or 24 hour p.i. Thus, the
combination of chemotherapeutic or targeted agents
and H-1PV enhanced the reduction of SK29-Mel cell
viability.
Analysis of DC activity: production of inflammatory
cyctokines and cross presentation
We next compared cytokine release of DC co-cultured
with different melanoma cell preparations (Figure 4A).
Levels of TNF-a and IL-6 were increased by a factor of
>1 7 8f o rT N F - a and a factor of > 36 for IL-6 when
immature DC were co-cultured with H-1PV-induced
SK29-Mel-1 cell lysates compared with control (mDC).
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SK29-Mel-1.22 and MZ7-Mel cells (data not shown).
As immature DC can process HLA-negative tumors
and present their TAAs in an HLA class I-restricted
manner to tumor-specific CTL by cross presentation
[32], we assessed whether phagocytosis of H-1PV-
induced lysates mediates cross presentation of TAAs to
CTLs. SK29-Mel-1.22 (HLA-A2
-)w e r ec o - c u l t u r e dw i t h
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+-restricted CTL to release cytokines on specific
recognition of SK29-Mel TAAs. A dramatic increase in
TNF-a levels following co-culture of CTL with DC
incubated with H-1PV-induced SK29 Mel-1.22 lysates
was observed (Figure 4B). The TNF-a level increased by
a factor of > 32. High levels of IL-6 (increased by a fac-
tor of > 3) were also observed in CTL co-cultures with
immature DC incubated with H-1PV-induced SK29-
Mel-1.22 TCL (Figure 4B). CTL co-culture controls with
immature DC and H-1PV, or immature DC and
untreated SK29-Mel-1.22 led to the release of only small
a m o u n t so fI L - 6a n dT N F - a, providing no evidence for
cross-presentation. Mature DC and H-1PV alone did
not increase the release of TNF-a or IL-6.
Activation of DC by different SK29-Mel cell preparations
To investigate the effects of different TCL preparations
on DC maturation, CD86 was quantified using FACScan
analysis. Immature DC were incubated for 2 days with
differentially treated melanoma cells. Preparations from
non-infected cells inducedm a t u r a t i o ni n~ 1 1 %o fD C
(data not shown). However, TCL from H-1PV-infected
melanoma cells led to 51% maturation of DC (Figure
5A). In contrast, cisplatin treatment alone of SK29-Mel
cells was as effective in inducing DC maturation (11%)
as untreated cells. Again, vincristinetreated SK29-Mel
cells did not significantly enhance CD86 expression
(19%). Immature DC incubated with SK29-Mel treated
with a combination of H-1PV and vincristine or H-1PV
and cisplatin enhanced CD86 expression compared with
the agents alone, although this was not as great as that
observed with TCL from H-1PV-infected SK29-Mel
cells alone. These findings suggest that H-1PV infection
of SK29-Mel cells compared with cisplatin and vincris-
tine treatment led to a greater positive effect on DC
maturation.
In the same model, SK29-Mel cells treated with suniti-
nib alone led to a slight increase in CD86-expression in
24% of DC (Figure 6A). However again, CD86 expres-
sion was significantly enhanced in immature DC co-cul-
tured with H-1PV-sunitinib-induced TCL (32%)
compared with sunitinib alone. So DC maturation
mediated using sunitinib-induced TCL can be clearly
enhanced by additional infection of melanoma cells with
H-1PV, providing a more effective immune response.
We lastly investigated the IL-6 production from CTL
co-cultured with immature DC and both melanoma
cells treated with chemotherapeutic agents and H-1PV.
Stimulation of DC with H-1PV-induced TCL led to
~11% increase in IL-6 production, which was similar to
that observed with H-1PV plus cisplatin or vincristine,
but appeared higher than with cisplatin alone (Figure
5B). Of note, IL-6 levels were also increased after co-
incubation of immature DC with sunitinib-treated
SK29-Mel cells and H-1PV-induced lysates compared
with H-1PV alone or sunitinib alone (Figure 6B). Very
similar results were obtained with MZ7-Mel cells (data
not shown).
Discussion
Current novel anticancer strategies aim to enhance both
apoptotic tumor cell death and immunologic tumor cell
recognition. Therefore oncolytic viruses are of increasing
clinical interest, [33,34] in particular, autonomous par-
voviruses, which appear very promising for tumor tar-
geting [8,10,26]. Since parvoviruses kill human cancer
cells through different pathways to other anticancer
therapies, we explored the impact and possible synergis-
tic effects between H-1PV and chemotherapeutic agents
or sunitinib, a typical molecule of the new multi-TK
inhibitors [35]. Sunitinib has activity against the signal-
ling pathways of vascular endothelial growth factor
(VEGF)-receptors as well as RAF, platelet-derived
growth factor receptor beta, fibroblast growth factor
receptor and stem cell factor receptor (c-KIT) across a
range of solid tumor types [36]. Preclinical and clinical
studies linked the antitumoral effects of sunitinib with
its inhibitory activity on these TKs [20].
We first confirmed that H-1PV-induced cell killing in
MZ7-Mel cells correlates with NS1-expression which is
consistent with other studies, and suggests that H-1PV
has high potential to achieve tumor suppression
[6,10,16,37]. Similarly, the combined treatment with H-
1PV and gemcitabine lead to toxicity in cell lines
regardless of used high doses of chemotherapeutic agent
and impaired virus replication [38]. Additionally, com-
bined treatment of the comparable adeno-associated
virus AAV-2 with cisplatin showed enhanced apoptosis
independent from cisplatin [33]. NS1 expression is
essential for transgene expression driven by recombinant
constructs. Previous studies have described how recom-
binant viruses containing MCP3 or IL-2 genes could sti-
mulate the immune system leading to additional
invasion of macrophages and NK cells in tumors [18].
Furthermore, the oncosuppressive capacity of CpG-
armed H-1PV vectors was tested in vivo in a rat hepa-
toma cell metastatic model and the therapeutic vaccina-
tion effect of the vector was accompanied by a strong
induction of cell mediated immune response [12].
We secondly combined antitumoral agents with onco-
lytic H-1PV. Here we investigated cisplatin and vincris-
tine, commonly used as anticancer treatment either in
combination or as monotherapy due to their different
modes of action [34,39]. The antitumor properties of
cisplatin are thought to be mediated via its ability to
form DNA adducts, including intra-and interstrand
DNA cross-links. Vincristine is a vinca-alkaloid, whose
mode of action occurs primarily through blocking the
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Page 9 of 14polymerization of tubulin, which suppresses microtubule
dynamics, halting mitosis and cell death [40]. The com-
bination of H-1PV with cisplatin or with vincristine
resulted in a reduced cell survival, which appeared addi-
tive at most doses studied. These cytotoxic effects may
depend on the p53 status of the cell lines, as cytotoxicity
of H-1PV has been shown to be more pronounced in
p53-negative than in p53-positive cells [11]. SK29-Mel
cells express the wildtype p53 gene [41] and a greater
effect may be observed in p53-negative cell lines. On the
other hand, Angelova et al showed that gemcitabine
resistance could efficiently be overcome by H-1PV [38].
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Page 10 of 14Again in a rabbit tumor model, the oncolytic pox virus
and expression of hGM-CSF from the virus induced
tumor-specific CTL and enhanced tumor-specific CTL
and antitumoral efficacy [42]. Even more, the vaccinia
virus (VV-CD) could demonstrate in vivo antitumor
effects when administered with 5-Flurocytidin (5FC)
even if 5-FC inhibited virus replication [43]. Further-
more in clinical trials with head and neck cancer
patients the oncolytic virus ONYX-015 was combined
with chemotherapy and clear benefits were observed in
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Page 11 of 14combination with cisplatin and 5-FU compared to
patients treated with chemotherapy alone [44,45]. CPA,
another alkylating agent like cisplatin, showed no effect
on immune cell infiltrates, viral replication or viral
transgene expression in experiments performed in non-
obese diabetes/severe combined immunodeficient mice
[46,47]. Rather combined immunosuppressive effects of
CPA correlated with increased viral transgene expres-
sion [48] and replication [49,50] in a variety of tumor
models. Moreover, adenvoiruses combined with cisplatin
presented in vitro a significant increase of apoptosis of
tumor cells but not normal cells in different tumor
models [51,52].
We next showed that phagocytosis of H-1PV-infected
MZ7-Mel-cells by DC was enhanced in concordance
with our previous data from other virus-infected cells
[6,8,53]. Thirdly, we analyzed DC maturation following
incubation with H-1PV-induced TCL by measuring the
expression of the maturation markers, CD80, CD83 and
CD86. DC incubated with H-1PV-induced MZ7-Mel
cell lysates resulted in a dramatic increase in the pro-
portion of DC expressing maturation markers, support-
ing similar data with other melanoma models, and
infection with the oncolytic reovirus [54]. However,
other viruses have been reported to directly infect DC
causing lysis and blocking important immune reactions
[55].
We observed CTL activation following co-incubation
with DC, which had phagocytosed H-1PV-infected
SK29-Mel cells, which could be due to cross-presenta-
tion. Activation occurred even if H-1PV alone was
unable to stimulate the DC and our data are supported
by other studies [53,56]. The increased release of pro-
inflammatory cytokines by DC indicates augmented
CD4
+ and CD8
+ T-cell activation. In vivo,t h i sm a y
lead to a response against TAAs [6,10,32,54]. As H-
1PV-induced melanoma lysates induced a much higher
level of phagocytosis by DC than either irradiated
(necrotic) or untreated cells, H-1PV may directly
enhance immune stimulation, which has also been
shown with other viruses [57]. Further, we observed
enhanced release of IL-6. Finally, there was a dramatic
increase of TNF-a and IL-6 following co-culture of
CTL with DC and lysates from H-1PV-infected mela-
noma cells. This is consistent with data from other
groups, where chemotherapeutic drugs like vincristine,
paclitaxel or methotrexate enhanced DC maturation
[58]. Pandha et al showed that treatment with cisplatin
increased the cytotoxicity of oncolytic reovirus but
effects on the immune system were negative. The cyto-
kine production induced by reovirus was suppressed
by cisplatin [59]. In our system, the comparable combi-
nation with H-1PV did not hinder the immune stimu-
latory effects.
We further investigated the use of sunitinib in combi-
nation with H-1PV in the melanoma cell line SK29-Mel.
We demonstrated that sunitinib decreases SK29-Mel
cell viability and that this is enhanced in combination
with H-1PV. It has previously been shown than suniti-
nib does not affect DC phenotype;[60] however, Finke et
al have reported impaired regulatory T-cell function
with sunitinib [61]. Furthermore, pretreatment with
sunitinib had no inhibitory effect on the ability of DC to
stimulate allogenic lymphocyte proliferation [60]. The
amount of viable immature DC were not affected by
sunitinib treatment, and it did not show any inhibitory
effects on maturation and function of DC, nor impair
the induction of primary T-cell responses in vivo.
Furthermore, it reduced the number of Tregs, which
constitute a major immune suppressive burden in can-
cer immune therapy [60]. However, the effect of suniti-
nib on the function of human immune responses has
not been evaluated in detail.
It could be postulated that combined oncolytic vir-
otherapy can amplify the role of anti-angiogenic therapy
by enhancing the effect of sunitinib and additional
tumor cell lysis. Furthermore, DC maturation by cells
treated with H-1PV, sunitinib and their combination
could be stimulated. This effect could also be shown by
the enhanced IL-6 production after the combined treat-
ment with H-1PV and sunitinib.
Conclusions
In conclusion, our experiments show that the combina-
tion of chemotherapeutic agents and the apathogenic
oncolytic H-1PV may enhance the tumor targeting
armamentarium and may preferentially attain immuno-
logically based long-term remission of cancer [31,62].
Presentation of TAAs, CTL activation and anti-TAA
responses should be presented as expectations for (i)
greater immunomodulatory and killing effects of H-1PV
compared with cisplatin and vincristine alone; and (ii)
increased cell killing effects by the combined treatment
with H-1PV and sunitinib. Furthermore, the use of
oncolytic viruses and anti-angiogenic agents in the treat-
ment of cancer could potentiate the particular effect. As
the first in vitro p r o o fo fc o n c e p t ,t h e s er e s u l t si n d i c a t e
that the immunomodulatory properties of H-1PV are
not disrupted by chemotherapeutic/targeted agents.
Even more H-1PV oncolytic activity reinforced drug-
induced tumor cell killing, suggesting the application of
this combination in tumor therapy could afford new
intriguing aspects in human cancer treatment.
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